Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Ho

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2021
Androgen Receptor Pathway in Salivary Gland CancerAlan L Ho
Endocrine|August 31, 2013
Moving toward a better understanding of radioiodine actionAlan L Ho
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlan L Ho
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancerAlan L Ho, Eric Sherman
Cancer Journal (Sudbury, Mass.)|September 27, 2022
Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future PromiseAntoine Desilets, Alan L Ho
BMJ Oncology|January 31, 2025
Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseasesAntoine Desilets, Alan L Ho
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?Alan L Ho, Gary K Schwartz
Journal of Oncology Practice|February 14, 2018
Challenges and Opportunities for Developing New Therapeutics for Salivary Gland CancersAlan L Ho, David G Pfister
JAMA|December 15, 2025
Head and Neck Cancer: A ReviewLara A Dunn, Alan L Ho, David G Pfister
Cell Cycle (Georgetown, Tex.)|February 2, 2012
The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependentJayasree S Nair, Alan L Ho, Gary K Schwartz
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2021
Androgen Receptor Pathway in Salivary Gland CancerAlan L Ho
Endocrine|August 31, 2013
Moving toward a better understanding of radioiodine actionAlan L Ho
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlan L Ho
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancerAlan L Ho, Eric Sherman
Cancer Journal (Sudbury, Mass.)|September 27, 2022
Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future PromiseAntoine Desilets, Alan L Ho
BMJ Oncology|January 31, 2025
Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseasesAntoine Desilets, Alan L Ho
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?Alan L Ho, Gary K Schwartz
Journal of Oncology Practice|February 14, 2018
Challenges and Opportunities for Developing New Therapeutics for Salivary Gland CancersAlan L Ho, David G Pfister
JAMA|December 15, 2025
Head and Neck Cancer: A ReviewLara A Dunn, Alan L Ho, David G Pfister
Cell Cycle (Georgetown, Tex.)|February 2, 2012
The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependentJayasree S Nair, Alan L Ho, Gary K Schwartz
Pageof 12